Verici Dx (LON: VRCI) continues to recover following last Wednesday’s operational announcement. Post kidney transplant rejection assessment product Tutiva has been launched and pre-transplant product Clarava should be launched before the end of 2023. The share price, up 57.1% to 11p, is the highest it has been since the beginning of February and 132% higher than one week ago when it reached an all-time low.
Immupharma (LON: IMM) has submitted a phase 2/3 clinical trial protocol to the FDA for testing Lupuzor as a treatment for lupus. A meeting with the FDA has been requested. The share price has jumped 17% to 2.1375p.
Publisher Merit Group (LON: MRIT) has negotiated an early end to the lease on office space and, after a move to a smaller office, this could save £1.4m a year. This follows the sale of the media, events and trading business for £4.5m. The share price rose 13.2% to 30p.
Good 2022 figures from Equals (LON: EQLS) have led to an upgrade for 2023 and it is acquiring Belgium-based global payments services provider Oonex for up to £4.1m. This deal has to be approved by the National Bank of Belgium and it provides better access to the European market. The 2023 pre-tax profit forecast has been increased from £15m to £17.4m, while earnings per share are raised by 10% to 7p – the lower percentage increase is due to the tax charge and a higher number of shares. The share price is 9.26% ahead at 88.5p. There is 10p a share in cash ahead of the latest acquisition.
Inland Homes (LON: INL) has exchanged contracts to sell 31 affordable homes to Eastlight Community Homes for £6.54m. These are part of the Templar Green development. The share price recovered by 5.77% to 5.5p.
Scottish gold producer Scotgold Resources (LON: SGZ) has been hit by falling ore grades at the Cononish gold mine. The average gold grade in January was 5.65g/t. compared with an estimated grade of 7.35g/t. A different part of the mine is being developed and the production process is being changed. Shore has its forecasts under review because of concerns about the financial position of the company. The share price slumped 63.2% to 14p.
Midatech Pharma (LON: MTPH) shares have fallen 18.4% to 15.5p following a 20-for-one share consolidation and ahead of the cancellation of the AIM quotation on 26 April. Shares in In The Style (LON: ITS) have fallen a further 22.5% to 0.465p even though shareholders voted against a cancellation of the AIM quotation.
Recruitment firm RTC Group (LON: RTC) had a better second half, but still reported a full year loss on lower revenues. The UK was hampered by rail strikes and higher costs, although recruitment demand relating to smart meter installation grew. International revenues slumped following the withdrawal of NATO from Afghanistan. Net debt increased to £2.7m. The share price declined by 10.8% to 16.5p.
There are delays to permits for the Clogau gold mine that is owned by Alba Mineral Resources (LON: ALBA) because of concerns about bats habitat. Management says that airborne geographical surveys of the Dolgellau gold exploration project could take place between June and August, depending on CAA authorisation. The share price slipped 8.16% to 0.1125p.
